Dambkowski Carl sold $2.5M of ORKA
Dambkowski Carl sold 35,000 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $70.13 ($70.11–$70.13, $2.45M total) across 2 trades over 2026-06-11 to 2026-06-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete, company-specific insider activity datapoint, but the 10b5-1 plan suggests the trades were scheduled in advance.
Market read
Traders may monitor for follow-on insider activity, but the 10b5-1 structure limits the signal’s strength.
What to watch
The filing does not disclose reasons for sale; traders should avoid extrapolating fundamentals from a single director’s planned disposal.
Background
This is an SEC Form 4 insider transaction disclosure for Oruka Therapeutics, Inc. (ORKA).
Ticker impact
Director Carl Dambkowski sold 35,000 ORKA shares in open-market trades for ~$2.45M under a pre-arranged 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven rather than fundamental.
The filing is primary-source and company-specific, but it is an open-market sale executed under a pre-arranged 10b5-1 plan, which typically dampens inference of new negative information.
Market effects
No clear sector read-through; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.
Key entities
- issuerOruka Therapeutics, Inc.
Subject of the Form 4 insider sale disclosure.
- insiderCarl Dambkowski
Director who sold ORKA shares in open-market transactions under a 10b5-1 plan.
